Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
CONCORDBIONSEConcord Biotech Limited· Pharmaceuticals & BiotechnologyHighPositive
Announced Wed, 10 Jun, 2026 · 10:13 IST

Concord Biotech gets USFDA approval for Tofacitinib Tablets 5mg and 10mg

Regulatory Product ApprovalBusiness Updates View source PDFExplain this filing

CONCORDBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+3.1%Reaction day
₹1280.30
prior close
₹1336.40
announcement price
In-mkt
timing
Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-1.1%+4.2% vs market
Pharmaceuticals peers, median of 164sector-0.6%+3.7% vs sector

On the reaction day the stock moved 4.2 pts more than Nifty Smallcap 250 and 3.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.2
10m
+0.0
15m
+0.2
30m
-0.8
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+3.1-1.1+4.2-0.6+3.7
Next day
+4.7-2.0+6.7-1.4+6.1
2d
+6.0+0.6+5.4-0.1+6.1
3d
+7.5+1.9+5.6+0.4+7.1
4d
+7.2+2.3+4.9+0.1+7.2
5d
+4.6+3.1+1.6+0.0+4.6
1w
+2.7+4.3-1.6+0.2+2.5
15d
+0.4+5.9-5.5+3.9-3.6
1m
+1.8+6.7-5.0+4.3-2.5
2m
+11.4+8.1+3.3+4.8+6.6
3m
+12.9+8.6+4.3+8.5+4.4
UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Concord Biotech has received USFDA approval for its ANDA for Tofacitinib Tablets in 5 mg and 10 mg strengths. These are used to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other conditions. The combined US market for both strengths is around US$ 500 million. The approval supports the company's US and international growth plans and broadens its product portfolio.

Likely market impact

Positive for growth and revenue potential, opens access to a US$ 500 million market opportunity